Aug 1, 2025 08:33AM Ocugen (OCGN) Tops Q2 EPS by 1c

Jul 21, 2025 07:30AM Ocugen adds retina experts to advisory board, names new executives

Jun 24, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Ocugen, Inc. (OCGN)

Jun 23, 2025 07:30AM Carisma Therapeutics (CARM) to Merge with Ocugen's (OCGN) OrthoCellix

Jun 16, 2025 07:03AM Ocugen (OCGN) Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Trial of OCU410ST

Jun 5, 2025 10:32AM Ocugen (OCGN) stock rises on Korean licensing deal for gene therapy

Jun 5, 2025 07:03AM Ocugen (OCGN) Signs Binding Term Sheet for the License of OCU400

May 27, 2025 07:04AM Ocugen (OCGN) Granted Rare Pediatric Disease Designation for OCU410ST

May 13, 2025 06:59AM Ocugen, Inc. (OCGN) PT Lowered to $7 at H.C. Wainwright

May 9, 2025 08:22AM Ocugen (OCGN) Tops Q1 EPS by 1c

Mar 18, 2025 08:06AM Ocugen (OCGN): Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 5, 2025 07:14AM Ocugen (OCGN) Tops Q4 EPS by 1c

Mar 3, 2025 09:01AM Ocugen (OCGN) Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for St

Feb 27, 2025 08:48AM Ocugen (OCGN) Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 13, 2025 06:50AM Ocugen, Inc. (OCGN) PT Raised to $8 at H.C. Wainwright

Feb 12, 2025 07:45AM Ocugen (OCGN) Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to dAMD

Feb 3, 2025 06:31AM Ocugen (OCGN) Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for OCU400

Jan 27, 2025 06:31AM Ocugen (OCGN) Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial of OCU500

Jan 13, 2025 06:31AM Ocugen (OCGN) Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400

Dec 19, 2024 06:40AM Ocugen (OCGN) Reports Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial

Nov 20, 2024 07:33AM Ocugen (OCGN) Granted EMA's Medicinal Product Designation for OCU410ST

Nov 19, 2024 07:03AM Ocugen (OCGN) Announces Compelling Preliminary Data for OCU410

Nov 8, 2024 06:53AM Ocugen (OCGN) reported Q3 Revenue

Oct 22, 2024 07:02AM Ocugen (OCGN) Reports Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Oct 15, 2024 08:18AM Maxim Group Starts Ocugen, Inc. (OCGN) at Buy

Oct 9, 2024 06:33AM Ocugen (OCGN) Announces Removal of Clinical Hold on OCU200

Aug 28, 2024 06:32AM Ocugen (OCGN) Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Trial

Aug 26, 2024 07:03AM Ocugen (OCGN) Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Aug 8, 2024 07:11AM Ocugen (OCGN) Tops Q2 EPS by 1c

Aug 5, 2024 06:31AM Ocugen (OCGN) Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

Aug 1, 2024 06:23AM Ocugen (OCGN) Prices 30.43M Share Offering at $1.15/sh

Jul 31, 2024 04:15PM Ocugen (OCGN) Announces Proposed Share Offering

Jun 26, 2024 04:38AM Increasing unusual put option volume: PTEN BMBL NXE FYBR BIG ALNY FND OCGN

Jun 21, 2024 07:01AM Ocugen (OCGN) Announces Data and Safety Monitoring Board Approved Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease